

Clinical Predictors of Left Main Coronary Artery Disease in High-Risk Patients With a First Episode of Non-ST-Segment Elevation Acute Coronary Syndrome

Eduard Claver, Antoni Curós, Jordi López-Ayerbe, Jordi Serra, Josepa Mauri, Eduard Fernández-Nofrerías, Oriol Rodríguez-Leor, Eva Bernal, and Vicente Valle

Servicio de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Introduction and objectives. Risk stratification in non-ST-elevation acute coronary syndrome makes use of clinical variables that can identify patients at an increased risk of complications. Our objective was to identify clinical variables that predict significant stenosis (i.e., >50%) of the left main coronary artery in high-risk patients who have had a first episode of non-ST-elevation acute coronary syndrome but who do not have a history of coronary artery disease.

Methods. The study included 102 high-risk patients with no history of coronary artery disease who were admitted because of non-ST-elevation acute coronary syndrome. All underwent coronary angiography. Patients were divided into 2 groups: those with significant left main coronary artery stenosis (n=14) and those without (n=88).

Results. Univariate analysis showed that the variables significantly associated with left main coronary artery stenosis were age >65 years (57.1% vs 15.9%; $P=.002$), diabetes mellitus (71.4% vs 33.0%; $P=.006$), chronic renal failure (28.6% vs 5.7%; $P=.019$), left heart failure (71.4% vs 6.8%; $P<.0001$), cardiogenic shock (21.4% vs 1.1%; $P=.008$), and a low left ventricular ejection fraction at admission (49.9% [14.7%] vs 58.8% [9.9%]; $P=.044$). In the multivariate analysis, the only significant independent predictor of left main coronary artery disease was left heart failure.

Conclusions. The presence of left heart failure at initial assessment of high-risk patients with non-ST-elevation acute coronary syndrome but without a history of coronary artery disease could be a useful predictor of significant left main coronary artery disease.

Key words: *Unstable angina. Coronary angiography. Coronary disease. Myocardial infarction. Heart failure. Prognosis. Left main coronary artery.*

Variables clínicas predictoras de enfermedad del tronco común en pacientes de alto riesgo con un primer episodio de síndrome coronario agudo sin elevación del segmento ST

Introducción y objetivos. En la estratificación del síndrome coronario agudo disponemos de variables clínicas para identificar a los pacientes con alto riesgo de presentar complicaciones. Analizamos si los pacientes de alto riesgo, sin antecedentes de cardiopatía isquémica, que presentan un primer episodio de síndrome coronario agudo sin elevación del segmento ST presentan variables clínicas predictoras de estenosis significativa (> 50%) del tronco común.

Métodos. Se analizó a 102 pacientes de alto riesgo sin antecedentes de cardiopatía isquémica con síndrome coronario agudo sin elevación del segmento ST, a los que se les practicó coronariografía. Establecemos 2 grupos: con estenosis significativa del tronco común (n = 14) y el resto (n = 88).

Resultados. Variables relacionadas con la estenosis del tronco común en el análisis univariado: edad > 65 años (el 57,1 frente al 15,9%; $p = 0,002$), diabetes mellitus (el 71,4 frente al 33,0%; $p = 0,006$), insuficiencia renal crónica (el 28,6 frente al 5,7%; $p = 0,019$), insuficiencia cardíaca izquierda (el 71,4 frente al 6,8%; $p < 0,0001$), shock cardiogénico (el 21,4 frente al 1,1%; $p = 0,008$) y fracción de eyección más reducida en el momento del ingreso ($49,9 \pm 14,7$ frente a $58,8 \pm 9,9$; $p = 0,044$). La única variable con valor predictivo significativo independiente de enfermedad del tronco común en el análisis multivariable fue la insuficiencia cardíaca izquierda.

Conclusiones. La presencia de insuficiencia cardíaca izquierda en la evaluación inicial del síndrome coronario agudo sin elevación del ST, en pacientes de alto riesgo sin antecedentes de cardiopatía isquémica, puede ser un predictor útil de enfermedad del tronco común.

Palabras clave: *Angina inestable. Coronariografía. Enfermedad coronaria. Infarto de miocardio. Insuficiencia cardíaca. Pronóstico. Tronco común.*

Correspondence: Dr. A. Curós.
Servicio de Cardiología. Hospital Universitari Germans Trias i Pujol.
Carretera del Canyet, s/n. 08916 Badalona. Barcelona. España.
E-mail: acuros@ns.hugtip.scs.es

Received October 13, 2005.
Accepted for publication April 25, 2006.

ABBREVIATIONS

RCA: right coronary artery.
 CX: circumflex artery.
 LAD: left anterior descending artery.
 NSTEMI-ACS: non-ST-segment elevation acute coronary syndrome.
 LMCA: left main coronary artery.

INTRODUCTION

A set of clinical, electrocardiographic, and biochemical variables is available in daily clinical practice to allow risk stratification of patients presenting with a non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). These variables are virtually the same as those appearing in the most widely used clinical guidelines for NSTEMI-ACS,¹⁻³ with only minimal, inconsequential variations between them.

These variables are the cornerstone of the initial work-up in these patients. In effect, depending on their presence or absence, it is possible to estimate the patient's short-term risk of presenting major cardiovascular events (death, myocardial infarction) and to establish patient groups according to whether the risk is low, intermediate or high. In addition, NSTEMI-ACS stratification allows optimization of treatment for these patients. Thus, in the high-risk group, in addition to conventional therapy, perfusion of glycoprotein IIb/IIIa inhibitors and urgent coronary revascularization would be indicated, with the aim of improving their prognosis.¹⁻³

The natural history of significant stenosis of the left main coronary artery (LMCA) without revascularization treatment is associated with elevated mortality in patients with stable coronary disease (50% at 3 years⁴) as well as those with acute coronary syndrome (ACS) (78.6% in patients with acute myocardial infarction [AMI] complicated by cardiogenic shock⁵). Stenosis of the LMCA is more frequent in high-risk patients with NSTEMI-ACS^{6,7}; hence, the possibility of predicting its presence is of maximum interest. The aim of this study, performed in patients with NSTEMI-ACS, no known history of ischemic heart disease, and classified as at high risk, was to analyze whether any of the clinical, electrocardiographic, or biochemical parameters we use to stratify risk in NSTEMI-ACS at hospital admittance is related with significant LMCA stenosis in the coronary angiography undertaken later.

METHODS

Patients

Between June 2000 and December 2004, 833 patients with NSTEMI-ACS were admitted to our

hospital coronary care unit. Their data were analyzed retrospectively and the following cases were excluded: patients with a history of ischemic heart disease, defined as those who had been hospitalized previously for myocardial infarction or unstable angina, patients treated with percutaneous or surgical coronary revascularization prior to the current event, and patients with significant valvular disease who had been diagnosed previously or during hospitalization. Patients presenting exertional angina who did not require hospital admittance with onset during the 2 months prior to the current hospitalization were, however, included. Among the total, 319 patients (38.3%) had none of the above-mentioned exclusion criteria. Of these, 102 were considered at short-term high-risk following the initial clinical assessment and comprised the study group.

Patients who presented the following factors were considered at high-risk: *a*) typical pain at rest that persisted despite medical treatment and involved a severe ST-segment decrease or signs of left heart failure (crepitant rales, third heart sound, or indicative features on the chest x-ray), hypotension, severe mitral regurgitation or sustained ventricular tachycardia; *b*) recurrent angina at rest despite optimal medical treatment, including intravenous nitroglycerin; *c*) angina at rest of less than 24 hours' evolution and more than 30 minutes' duration with ST segment decrease ≥ 2 mm in the anterior territory, or transient ST segment elevation; and *d*) angina of less than 24 hours' evolution with ST segment decrease < 2 mm or with a pronounced negative T-wave in the anterior territory, with positive biochemical necrosis markers (creatinine kinase MB isoenzyme [CK-MB] and/or troponin I), age > 65 years or diabetes, and at least one of the following variables on the initial work-up: ejection fraction known to be $\leq 40\%$ or peripheral vascular disease (defined as peripheral vascular murmur, intermittent claudication of the lower limbs, or history of peripheral vascular surgery).

The presence of chronic renal failure is not formally contemplated for risk stratification in the NSTEMI-ACS guidelines.¹⁻³ Nevertheless, because of the growing evidence linking this condition with a poorer prognosis in patients presenting an ischemic event,^{8,9} we have included this factor in the present study as a clinical variable that should be taken into consideration in the initial assessment of these patients.

Experimental Methods

The first electrocardiogram performed in each patient following hospital admission was taken as a reference. The anterior territory was defined as the electrocardiographic tracings obtained with the V1, V2, V3, and V4, leads, the lateral territory

corresponded to the I, aVL, V5, and V6 tracings and the inferior territory, to the II, III, and aVF tracings. Myocardial necrosis markers were considered pathological when the troponin I value was >0.5 ng/mL (Dade Behring, United Kingdom) and/or CK-MB was >5 ng/mL (Dade Behring, United Kingdom), provided the fraction represented more than 5% of the total CK. Plasma determinations of the myocardial necrosis markers were performed on three occasions, every 8 hours from the time of onset of the chest pain that led to the patient's hospitalization.

The drugs commonly used for NSTEMI-ACS, administered during the interval between hospital admission and the coronary angiography examination, were recorded to compare the homogeneity of the medical treatment between patients with and without LMCA disease.

Coronary angiography was done within the first 48 hours after hospitalization in all selected high-risk patients with NSTEMI-ACS, according to the aforementioned criteria. Depending on the result obtained, 2 patient groups were established: those with significant LMCA stenosis and the remaining patients. A lesion was considered to be angiographically significant when $\geq 50\%$ of the diameter of the vessel lumen was compromised on at least 2 different views in the case of the LMCA and $\geq 70\%$ for the remaining coronary arteries, using as a reference the adjacent segment of the vessel without angiographic lesions.¹⁰ The criteria most frequently used to establish the percentage of stenosis was the subjective assessment of any of the 3 experienced interventional radiologists who performed the coronary cardiologist. In 15 patients (14.7%), intracoronary ultrasonography was also used. In this case a lesion was considered significant when the lumen area of the stenotic vessel segment was <6 mm² in the LMCA¹¹ or <4 mm² in the remaining vessels.^{12,13}

The analyses (univariate and multivariate) include the quantitative results of the first left ventricular ejection fraction in each patient, as measured by contrast ventriculography in the catheterization laboratory or by echocardiography in certain patients with renal failure who could not undergo this method.

Statistical Analysis

The results are expressed as the mean \pm standard deviation for quantitative variables and as percentages with the 95% confidence interval (CI), obtained with the exact binomial method, for qualitative variables. Student's *t* test was used for comparisons between quantitative variables and the χ^2 test for comparisons between qualitative variables. To assess their independence, variables attaining statistical significance in the univariate analysis were introduced in the multivariate logistic regression model by the

forward stepwise method, with the criterion of 0.05 for entrance and 0.10 for elimination from the model. SPSS for Windows, version 11.0 (SPSS, Chicago, USA) was used for the analyses. Statistical significance was set at $P=.05$.

RESULTS

Demographic Characteristics

Among the total of 102 high-risk patients with NSTEMI-ACS and no known history of ischemic heart disease, 83 were men. The mean age was 57.1 ± 10.1 years. It is noteworthy that nearly all the patients (94%) showed alterations indicative of ischemia on the electrocardiogram and the majority had prolonged chest pain (72%) that appeared at rest (80%) and was associated with elevated myocardial necrosis markers (61%). The percentages at which the various drugs were administered in the 2 patient groups (with and without LMCA disease) are shown in Table 1.

Results of Coronary Angiography

Fourteen patients had significant LMCA stenosis and constituted the study group (Table 2). Among these patients, 2 had no other angiographically significant lesions, 7 had additional lesions in 3 coronary arteries (left anterior descending artery [LAD], circumflex artery [CX], and right coronary artery [RCA]), 4 had lesions in 2 vessels (1 CX and RCA and 3 LAD and CX), and 1 patient had a lesion in 1 vessel (CX). The remaining patients comprised the group without LMCA disease ($n=88$, 86.3%).

TABLE 1. Percentage of Drugs Administered in High-Risk Patients With NSTEMI-ACS With and Without Significant Left Main Coronary Artery Disease, During the Interval Between Hospital Admission and the Coronary Angiography Study*

Drug Administered	LMCA Disease (n=14)	No LMCA Disease (n=88)	P
Aspirin, %	100.0	97.7	1.00
Clopidogrel, %	64.3	50.0	.32
Nitroglycerin, %	100.0	98.8	1.00
Beta blockers, %	50.0	73.3	.08
Calcium-channel blockers, %	7.1	16.3	.38
Heparin, %	92.9	91.9	1.00
Glycoprotein IIb/IIIa receptor antagonists/inhibitors?, %	21.4	13.6	.43
Diuretics, %	57.1	9.2	$<.001$
Inotropic agents (dopamine or dobutamine), %	21.4	1.2	.008
ACE inhibitors, %	18.2	15.3	.68

*ACE indicates angiotensin-converting enzyme; NSTEMI-ACS, non-ST-segment elevation acute coronary syndrome; LMCA, left main coronary artery.

TABLE 2. Results of Coronary Angiography in High-Risk Patients With NSTEMI-ACS and No Known History of Ischemic Heart Disease (n=102)*

Coronary Angiography Result	Patients (n=102)	%	95% CI
Without significant angiographic lesions	4	3.9	1-8
Single-vessel coronary disease†	38	37.3	29-48
Two-vessel/CHECK THIS coronary disease‡	20	19.6	12-28
Three-vessel coronary disease‡	26	25.5	18-35
Left main coronary artery disease‡	14	13.7	8-21

*CI indicates confidence interval; NSTEMI-ACS, non-ST-segment elevation acute coronary syndrome.

†Stenosis >70%.

‡Stenosis >50%.

Among the patients with single-vessel disease (n=38, 37.3%), 21 had a lesion in the LAD, 10 in the CX and 7 in the RCA. Among the patients with 2-vessel disease (n=20, 19.6%), 8 had lesions in the RCA and LAD, 7 in the LAD and CX, and 5 in the RCA and CX.

Relationship Between the High-Risk Variables and Left Main Coronary Artery Disease

In the univariate analysis, the following clinical variables used in the initial risk stratification showed a statistically significant association with the presence of LMCA: age >65 years at the time of the event, history of diabetes mellitus, chronic kidney failure, signs of left heart failure detected at the time of hospital admittance, cardiogenic shock at hospitalization, and lower left ventricular ejection fraction. There were no significant differences between the groups with respect to the duration of chest pain that led to hospitalization, appearance of pain while at rest, recurrence of pain despite intravenous nitroglycerin administration, or presence of ventricular arrhythmia in the first 24 hours of the ischemic event. None of the electrocardiographic alterations analyzed were associated with the presence of LMCA disease, although patients with this condition showed a non-significant trend toward presenting a more highly depressed ST segment. None of the territories showing electrocardiographic signs of ischemia were associated with the group having LMCA disease. Maximum plasma concentrations of myocardial necrosis markers were not higher in patients with LMCA disease (Table 3).

In the logistic regression analysis of variables that were statistically significant in the univariate analysis, the only variable with a significant independent predictive value for LMCA disease was the presence of left heart failure at the time of hospitalization (odds ratio [OR]=32.5; 95% CI, 7.8-135.3; $P<.0001$).

DISCUSSION

In this study, involving 102 high-risk patients with NSTEMI-ACS and no history of ischemic heart disease as defined above, 13.7% presented significant LMCA stenosis, a percentage similar to the 16% of LMCA involvement encountered in a recently published study⁶ performed in 103 patients with NSTEMI-ACS at high risk according to the TIMI scale.¹⁴ In the same study, patients considered to be at low or intermediate risk presented 3% and 7%, respectively, of significant LMCA disease. In the PRISM-PLUS study,⁷ the proportion of patients with significant LMCA disease was 10% in the group with highest values on the TIMI scale, and 4% in the groups with lower scores.

Age >65, one of the parameters used in the TIMI risk scale,¹⁴ was related with LMCA disease in the univariate analysis in our series. The results of the classic CASS¹⁵ study have already shown an association between advanced age and the presence of LMCA disease. Chronic renal failure and diabetes mellitus were also significantly associated with disease of the LMCA. The association between these risk factors and the presence of severe coronary disease is well recognized.^{8,9,16,17}

With regard to the prognostic importance of heart failure in NSTEMI-ACS, the GRACE registry¹⁸ disclosed a significant association between signs of left heart failure at the time of hospitalization and in-hospital and out-of-hospital mortality. In addition, the prognostic value of the Killip classification¹⁹ was well-established for NSTEMI-ACS in a recent, extensive meta-analysis²⁰ in which it was an independent predictor of short- and long-term mortality, with greater prognostic value than electrocardiographic alterations or elevated myocardial necrosis markers. Thus, the search for signs of left heart failure in the initial work-up of patients with NSTEMI-ACS is important. Moreover, it is well recognized that because of the poor short- and medium-term prognosis of patients with NSTEMI-ACS and left heart failure, an early revascularization strategy is clearly beneficial²¹⁻²³ for these individuals.

We found no relationship between ST-segment elevation in the aVR lead and LMCA disease. A relationship between these factors was reported in a study containing a larger number of patients.²⁴ The presence of signs of left heart disease in subjects with non-Q-wave myocardial infarction was associated with the grade of ST-segment elevation in the aVR lead, and this, in turn, was related with the presence of severe coronary disease (3-vessel or LMCA disease).

In our series, signs of left heart failure in the initial work-up of high-risk patients presenting NSTEMI-ACS were predictive of LMCA disease. Nevertheless, it should be taken into account (as stated in the *Limitations* section) that these results must be interpreted in the light of the small size of the sample.

TABLE 3. High-Risk Patients With NSTEMI-ACS and No History of Ischemic Heart Disease (n=102) Stratified According to the Criteria Stated in the *Methods* Section. Associations of the Various Clinical, Electrocardiographic, and Biochemical Variables Obtained in the Initial Work-Up With the Presence of Significant Left Main Coronary Artery Disease*

	LMCA Disease (n=14)	No LMCA Disease (n=88)	P
Clinical variables			
Men, %	64.3	84.1	.131
Age >65 years, %	57.1	15.9	.002
Diabetes mellitus, %	71.4	33.0	.006
Peripheral vascular disease, %	42.9	19.3	.080
Dialysis, %	14.3	3.4	.138
Chronic renal failure, %	28.6	5.7	.019
Chest pain >30 min, %	78.6	70.5	.536
Chest pain appearing at rest, %	92.9	78.4	.210
Left heart failure, %	71.4	6.8	<.0001
Recurrent chest pain, %	21.4	44.3	.106
Recurrent chest pain with ECG signs of ischemia, %	14.3	35.2	.070
Cardiogenic shock, %	21.4	1.1	.008
Ventricular arrhythmia, %	0.0	1.1	.692
Ejection fraction, %	49.9	58.8	.044
Electrocardiographic variables			
T-wave changes, %	7.1	19.3	.24
Transient ST-segment elevation, %	7.1	23.9	.06
Depressed ST-segment depression, %	64.3	45.5	.190
Grade of ST-segment depression, mm	2.2	1.6	.098
ECG inferior wall changes, %	35.7	21.6	.252
ECG lateral wall changes, %	57.1	54.6	.858
ECG anterior wall changes, %	50.0	56.8	.637
Biochemical variables			
Maximum troponin I peak, ng/mL	36.4	5.6	.110
Maximum CK-MB peak, U/L	40.3	22.6	.139

*CK-MB indicates creatinine kinase MB isoenzyme; ECG, electrocardiogram; NSTEMI-ACS, non-ST-segment elevation acute coronary syndrome; LMCA, left main coronary artery.

The patients analyzed herein had no known history or echocardiographic signs of having presented prior episodes of myocardial infarction. Thus, it is reasonable to believe that they had no previous areas of myocardial necrosis that could have independently contributed to the left ventricular dysfunction, apart from the current process.

Myocardial ischemia is initially accompanied by diastolic ventricular dysfunction due to decreased ventricular relaxation, with a left displacement of the diastolic pressure-volume curve, such that the ventricular diastolic pressure is greater for any given diastolic volume.²⁵ When the ischemia persists, the myocardial contractile capacity decreases and systolic dysfunction develops. In an ischemic event able to alter left ventricular functionality and trigger left heart failure, there must be a considerable proportion of dysfunctional left ventricular myocardium caused by the ischemia. It has been estimated that clinical manifestations of left heart failure appear when about 25% of the left ventricular myocardium is compromised, and if the compromise reaches 40%, cardiogenic shock usually develops.²⁶ The LMCA

irrigates a high percentage of at-risk myocardium. In fact, the severe, acute left ventricular contractile deficit that causes the development of cardiogenic shock or acute pulmonary edema is virtually the norm in ST-segment elevation AMI when the LMCA is the culprit vessel.²⁷⁻³¹

According to data from the SHOCK⁵ study, hospital mortality is 78.6% in patients with AMI caused by an LMCA lesion and complicated by cardiogenic shock. A decrease in hospital mortality to 55%-58%^{27,28} has been reported when percutaneous revascularization is applied in patients with AMI due to a LMCA lesion, the majority complicated by cardiogenic shock. In 2 recently published studies in our setting involving patients with unstable angina or AMI who were treated with a percutaneous LMCA procedure either because they were not candidates for surgery or because they required emergency interventional procedures,^{32,33} the documented mortality was between 45.4% and 55%. Nevertheless, the literature shows a generalized underuse of revascularization procedures in patients with an ischemic event complicated by left heart failure or cardiogenic shock.^{17,34}

Generally, the artery causing acute myocardial ischemia in NSTEMI-ACS does not present complete lumen occlusion and the clinical manifestations tend to be less severe than those seen in ST-segment elevation infarction. For example, in the GUSTO-IIb study,³⁵ patients presenting ACS with ST-segment elevation at the time of hospitalization developed cardiogenic shock more frequently (4.2%) than those without ST-segment elevation (2.5%).

Lastly, it should be pointed out that the medical treatment given was similar between the 2 groups studied (with and without significant LMCA involvement), except in the use of diuretics and inotropic drugs (dopamine and dobutamine), which were administered more frequently in the group of patients with LMCA disease (Table 1).

CONCLUSIONS

In high-risk patients with no history of ischemic heart disease presenting with NSTEMI-ACS, the presence of signs of left heart disease in the initial work-up was a useful predictor of LMCA disease. In the light of these results, we believe it is worthwhile to perform emergency coronary angiography in these patients, given their poor prognosis and the possibility for improvement with therapeutic procedures such as surgical or percutaneous revascularization.

Limitations of the Study

This study has the limitations inherent to a retrospective analysis of the clinical data obtained in a single center and a small sample size. This latter aspect is a quantitative limitation, but it is also an accurate reflection of our patient population and the diagnostic and therapeutic interventions we use.

REFERENCES

- López L, Arós F, Lidón RM, Cequier A, Bueno H, Alonso J, et al. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. *Rev Esp Cardiol.* 2002;55:631-42.
- Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. *Eur Heart J.* 2002;23:1809-40.
- Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol.* 2002;40:1366-74.
- Cohen MV, Gorlin R. Main left coronary artery disease: clinical experience from 1964-1974. *Circulation.* 1975;52:275-85.
- Wong SC, Sanborn T, Sleeper LA, Webb JG, Pilchik R, Hart D, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded Coronaries for cardiogenic shock? *J Am Coll Cardiol.* 2000;36 Suppl A:1077-83.
- García S, Canoniero M, Peter A, de Marchena E, Ferreira A. Correlation of TIMI risk score with angiographic severity and extent of coronary artery disease in patients with non-ST-elevation acute coronary syndromes. *Am J Cardiol.* 2004;93:813-6.
- Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, et al. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Am Heart J.* 2005;149:846-50.
- Freeman RV, Metha RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. *J Am Coll Cardiol.* 2003;41:718-24.
- Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insufficiency and mortality from acute coronary syndromes. *Am Heart J.* 2004;147:623-9.
- The Principal Investigators of CASS and Their Associates. The National Heart, Lung and Blood Institute Coronary Artery Surgery Study: historical background, design, methods, the registry, the randomised trial, clinical database. *Circulation.* 1981;63 Suppl 1:1-81.
- Jasti V, Yalamanchili V, Ivan E, Merrill B, Chandra M, Leesar MA. Fractional flow reserve versus intravascular ultrasound for decision-making in equivocal left main coronary stenosis. *J Am Coll Cardiol.* 2004;44 Suppl 1:92.
- Abizaid A, Mintz GS, Pichard AD, Kent KM, Satler LF, Walsh CL, et al. Clinical, intravascular ultrasound, and quantitative angiographic determinants of the coronary flow reserve before and after percutaneous transluminal coronary angioplasty. *Am J Cardiol.* 1998;82:423-8.
- Nishioka T, Amanullah A, Luo H, Berglund H, Kim CJ, Nagai T, et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. *J Am Coll Cardiol.* 1999;33:1870-8.
- Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/Non-ST elevation MI. A method for prognostication and therapeutic decision making. *JAMA.* 2000;284:835-42.
- Chaitman BR, Bourassa MG, Davis K, Rogers WJ, Tyras DH, Berger R, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). *Circulation.* 1981;64:360-7.
- Theroux P, Alexander Jr J, Pharand C, Barr E, Snapinn S, Ghannam A. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction. Results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study. *Circulation.* 2000;102:2466-72.
- Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *J Am Coll Cardiol.* 1997;30:171-9.
- Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, et al. Determinants and prognostic impact

- of heart failure complicating acute coronary syndromes. Observations from the global registry of acute coronary events (GRACE). *Circulation*. 2004;109:494-9.
19. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. *Am J Cardiol*. 1967;20:457-64.
20. Khot UN, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, Topol EJ. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. *JAMA*. 2003;290:2174-81.
21. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators: Fast Revascularisation during Instability in Coronary artery disease. *Lancet*. 2000;356:9-16.
22. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344:1879-87.
23. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA-3 randomised trial. Randomised Intervention Trial of unstable Angina. *Lancet*. 2002;360:743-51.
24. Barrabés JA, Figueras J, Moure C, Cortadellas J, Soler-Soler J. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarction. *Circulation*. 2003;108:814-9.
25. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium: effects of reperfusion of arterial blood. *Circulation*. 1983;68 Suppl I:25.
26. Rackley CE, Russell RO Jr, Mantle JA, Rogers WJ. Modern approach to the patient with acute myocardial infarction. *Curr Probl Cardiol*. 1977;1:1-47.
27. Marso SP, Steg G, Plokker T, Holmes D, Park SJ, Kosuga K, et al. Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the Ultima experience). *Am J Cardiol*. 1999;83:1513-7.
28. de Luca G, Suryapranata H, Thomas K, van't Hof AW, de Boer MJ, Hoorntje JC, et al. Outcome in patients treated with primary angioplasty for acute myocardial infarction due to left main coronary artery occlusion. *Am J Cardiol*. 2003;91:235-8.
29. Quigley R, Milano C, Smith R, White W, Rankin S, Glower D. Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock. *Circulation*. 1993;88 Suppl 2:65-70.
30. Spiecker M, Erbel R, Rupprecht HJ, Meyer J. Emergency angioplasty of totally occluded left main coronary artery in acute myocardial infarction and unstable angina pectoris-institutional experience and literature review. *Eur Heart J*. 1994;15:602-7.
31. Hon-Kan Y, Chiung-Jen W, Mien-Cheng C, Hsueh-Wen C, Kelvin H, Chi-Ling H, et al. Effect of primary angioplasty on total or subtotal left main occlusion. *Chest*. 2001;120:1212-7.
32. Martí V, Planas F, Cotes C, García J, Guiteras P, López L, et al. Resultados inmediatos y a largo plazo de la angioplastia con stent en el tronco común. *Rev Esp Cardiol*. 2004;57:1029-34.
33. López-Palop R, Pinar E, Saura D, Pérez-Lorente F, Lozano I, Teruel F, et al. Resultados a corto y medio plazo del intervencionismo coronario percutáneo sobre el tronco coronario común izquierdo no protegido en pacientes malos candidatos para revascularización quirúrgica. *Rev Esp Cardiol*. 2004;57:1035-44.
34. Rohlfs I, Elosua R, Masià R, Sala J, Marrugat J, en representación de los investigadores del REGICOR. Tendencias en la proporción de pacientes menores de 75 años con infarto agudo de miocardio que presentan Killip III-IV. Variables asociadas con su aparición y con el pronóstico: 1978-1997. *Rev Esp Cardiol*. 2002;55:1117-23.
35. Holmes DR Jr, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. *Circulation*. 1999;100:2067-73.